Differential sensing, inspired by the olfactory systems in mammals, utilizes the cross‐reactivity of multiple sensor units toward analytes to generate a distinctive fingerprint for each analyte. Widely acknowledged as a robust analytical technique, differential sensing has entered a flourishing era with the advancement of machine learning. Nevertheless, developing sensor units and optimizing signal transduction remain significant tasks left to chemists. Macrocyclic receptors serve as promising materials for constructing sensor arrays with enhanced cross‐reactivity, facilitated by their ease of synthesis and derivatization, inherent broad‐spectrum encapsulation capability, and compatibility with multiple responsive signal transduction approaches. Herein, we present a concise overview of the fundamental processes involved in a sensor array, encompassing array construction, signal transduction, and data acquisition and analysis, with an emphasis on the unique advantages provided by macrocyclic receptors in the former two aspects. Then, we present fascinating application scenarios where macrocyclic receptors shine in differential sensing that rely on various ingenious sensing strategies. Finally, we discuss several issues with potential improvement and future directions for macrocyclic receptor‐based differential sensing, offering a forward‐looking perspective.
2 May 2014 in Journal of Geophysical Research: Space Physics
In the work, we have experimentally investigated the boundary layer processes of artificially created ionospheric depletions. Those ionospheric depletions were modeled via releasing attachment chemicals, such as SF6,CF4, and CO2, into the ambient plasmas. Boundary layer of width of electric scale length emerged and separated those plasmas into two regions, the ambient plasmas and the negative ions plasmas. In the localized boundary layer, those fluctuations of the electron density and the floating potential were investigated varying with the plasma pressure and the partial pressure of released chemicals. The electron density decreased sharply that yielded steep density gradients ∇ne, and the floating potential increased which generated sheared electron flows. It is found that the magnitude of fluctuating floating potential is proportional to that of the ∇ne. Those fluctuations were analyzed in detail using digital spectra analysis techniques. Vortex‐like coherent structures were observed in the fluctuations of electrostatic potentials. These coherent frequencies are sensitive to the mass of the negative ions, and all lie in the lower hybrid range. By comparing the experimental results with theoretical predictions, the modes have been identified as the coherent structures resulting from the electron‐ion hybrid instability. Our results are important to study the early phase nonlinear evolution of the ionospheric depletion and also may be applied to the plasma sheet boundary layer in where often encounters the narrow electron density gradients and sheared electron flows.
Ischemic injury induces a partial mesenchymal shift in endothelial cells (ECs), contributing to impaired vascular regeneration. However, the molecular regulators of this transitional state remain poorly defined. To address this, we performed circular RNA profiling of endothelial cells under ischemic-like conditions and identified a marked upregulation of a circular RNA, named circATXN1. Functional studies revealed that circATXN1 knockdown modulates endothelial phenotype and vascular response after ischemia. Functional studies have shown that knockdown of circATXN1 can regulate the endothelial cell phenotype and vascular response after ischemia. Mechanistically, circATXN1 knockdown enhances the demethylase protein ALKBH5 to reduce the RNA methylation level of the key transcription factor SLUG, thereby stabilizing SLUG. In animal models, suppression of circATXN1 enhances angiogenesis and improves recovery following ischemic injury. Here, we show that circATXN1 regulates partial endothelial-to-mesenchymal transition (EndMT) and angiogenesis by controlling SLUG mRNA methylation dynamics, highlighting its potential as a therapeutic target in ischemic disease.
5 August 2023 in Forensic Science, Medicine and Pathology
Due to nonspecific pathological changes and the rapid degradation of insulin in postmortem blood samples, the identification of the cause of death during insulin overdose has always been a difficulty in forensic medicine. At present, there is a lack of studies on the toxicological changes and related mechanisms of an insulin overdose, and the specific molecular markers of insulin overdose are still unclear. In this study, an animal model of insulin overdose was established, and 24 SD rats were randomly divided into a control group, insulin overdose group, and a recovery group (n = 8). We detected the biochemical changes and analyzed the toxicological mechanism of an insulin overdose. The results showed that after insulin overdose, the rats developed irregular convulsions, Eclampsia, Opisthotonos, and other symptoms. The levels of glucose, glycogen, and C-peptide in the body decreased significantly, while the levels of lactate, insulin, and glucagon increased significantly. The decrease in plasma K+ was accompanied by the increase in skeletal muscle K+. The PI3K-AKT signaling pathway was significantly activated in skeletal muscle, and the translocation of GLUT4/Na+-K+-ATPase to sarcolemma was significantly increased. Rare glycogenic hepatopathy occurred in the recovery group after insulin overdose. Our study showed that insulin overdose also plays a role in skeletal muscle cells, mainly through the PI3K-Akt signaling pathway. Therefore, the detection of signaling pathway proteins of the skeletal muscle cell membrane GLUT4 and Na+-K+-ATPase has a certain auxiliary diagnostic value for forensic insulin overdose identification. Glycogen detection in the liver and skeletal muscle is important for the diagnosis of insulin overdose, but it still needs to be differentiated from other causes of death. Skeletal muscle has great potential for insulin detection, and the ratio of insulin to the C-peptide (I:C) can determine whether an exogenous insulin overdose is present.
BACKGROUND: Cardiac hypertrophy is one of the major causes of heart failure and sudden cardiac death. OTUD7a (OTU domain–containing protein 7a) is identified as a deubiquitinizing enzyme and a possible tumor suppressor. The present study is aimed at exploring the potential role and key downstream effectors of OTUD7a in cardiac hypertrophy. METHODS: The expression level of OTUD7a was detected in the cardiomyocytes with phenylephrine stimuli and the hearts subjected to transverse aortic constriction surgery. Then, the potential effects of OTUD7a on cardiac hypertrophy were evaluated in vivo by using cardiac-specific OTUD7a knockout mice and adeno-associated virus serotype 9-OTUD7a–infected mice. To further explore the direct modulation of OTUD7a on cardiomyocytes, hypertrophic parameters were detected in phenylephrine-stimulated cardiomyocytes with adenovirus system–induced OTUD7a overexpression or depletion. Furthermore, RNA-sequencing and interactome analysis, which were followed by multiple molecular biological methodologies, were combined to identify the direct target and corresponding molecular events contributing to OTUD7a function. RESULTS: Cardiac hypertrophy stimulates expression of OTUD7a in vitro and in vivo. Our data clearly showed that OTUD7a deficiency alleviates pathological cardiac hypertrophy in the transverse aortic constriction mouse model as well as in phenylephrine-treated cardiomyocytes, whereas overexpression of OTUD7a aggravated hypertrophic heart in vivo and enhanced cardiomyocyte enlargement in vitro. Mechanistically, TAK1 (transforming growth factor-β–activated kinase 1) was identified as a direct and essential target of OTUD7a in cardiac hypertrophy. To be more specific, OTUD7a directly interacts with TAK1 to inhibit the ubiquitination degradation of TAK1 and subsequently increase the phosphorylation levels of TAK1 and its downstream JNK (c-Jun N-terminal kinase)/P38. 5Z-7-oxozeaenol, a TAK1 inhibitor, blocked the detrimental effects of OTUD7a. Moreover, overexpression of TAK1 abolished the protection of OTUD7a depletion. CONCLUSIONS: Our findings, for the first time, provide evidence supporting OTUD7a as a novel promoter of pathological cardiac hypertrophy and indicate that targeting the OTUD7a-TAK1 axis represents a promising therapeutic strategy for cardiac hypertrophy and related heart failure.